Company Profile
Nuvation Bio Stock Price, News & Catalysts
- Ticker:
- NUVB
- Exchange:
- NYSE
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.88 USD (-1.41%)
Close
Last updated: October 6, 2026
1.71B USD
Market cap
Why the stock is moving
As of Oct 6, 2026, NUVB closed down 1.41% at $4.88. No new same-company headline was identified in the current news window.
Company overview
Global Oncology Company
Nuvation Bio develops and commercializes targeted therapies for cancers with defined molecular drivers. The portfolio includes a commercial ROS1 inhibitor, a clinical-stage IDH1 inhibitor for glioma, and earlier drug-drug conjugate programs.
IBTROZI for ROS1-Positive Lung Cancer
IBTROZI, or taletrectinib, is an oral, central-nervous-system-active ROS1 inhibitor approved in the United States for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer. Its development program includes both treatment-naive patients and patients previously treated with a ROS1 tyrosine kinase inhibitor.
Commercial Oncology Infrastructure
The IBTROZI launch gives Nuvation Bio a direct commercial presence in thoracic oncology. The company supports prescribing through specialist engagement, diagnostic testing, market access, and patient services while pursuing additional geographic and label opportunities for taletrectinib.
Safusidenib in IDH1-Mutant Glioma
Safusidenib is a brain-penetrant inhibitor of mutant IDH1 being developed for IDH1-mutant glioma. Following durable Phase 2 activity, the company expanded development into a pivotal ex-U.S. Phase 3 study in grade 2 disease and a U.S. Phase 2 study in patients previously treated with vorasidenib.
Earlier Drug-Drug Conjugate Portfolio
Nuvation Bio is also developing drug-drug conjugates designed to combine two active small molecules in a single tumor-targeted construct. These earlier programs provide additional oncology optionality beyond the ROS1 and IDH1 franchises.
Future catalysts
- FDA PDUFA decision on the IBTROZI supplemental NDA on January 4, 2027.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Nuvation Bio (NUVB)?
Nuvation Bio (NUVB) most recently closed at 4.88 USD, a -1.41% move versus the previous session.
What is the market cap of Nuvation Bio (NUVB)?
Nuvation Bio currently has a market capitalization of 1.71B USD on BioPharmSignal.
What does Nuvation Bio do?
Global Oncology Company Nuvation Bio develops and commercializes targeted therapies for cancers with defined molecular drivers. The portfolio includes a commercial ROS1 inhibitor, a clinical-stage IDH1 inhibitor for glioma, and earlier drug-drug conjugate programs. IBTROZI for ROS1-Positive Lung Cancer IBTROZI, or taletrectinib, is an oral,...
On which exchange is NUVB stock listed?
Nuvation Bio (NUVB) is associated with NYSE, United States, Biopharma.
What is taletrectinib?
IBTROZI for ROS1-Positive Lung Cancer IBTROZI, or taletrectinib, is an oral, central-nervous-system-active ROS1 inhibitor approved in the United States for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
Which conditions is Nuvation Bio targeting with taletrectinib?
Nuvation Bio is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Nuvation Bio describe recent progress with taletrectinib?
FDA PDUFA decision on the IBTROZI supplemental NDA on January 4, 2027.
What is vorasidenib?
Phase 2 study in patients previously treated with vorasidenib.